Skip to main content

Table 3 Studies comparing the prognostic value of synchronous vs. metachronous detection of CRCLM published in 2005–2018

From: Synchronous and metachronous liver metastases in patients with colorectal cancer—towards a clinically relevant definition

Reference Year of publication Cohort Definition* Synchronous/metachronous OS DFS
Mutsaerts et al. [16] 2005 Operated 2 43/59 S (p = 0.048) NR
Leporrier et al. [17] 2006 All 3 250/108 NS (p = 0.498) NR
Minagawa et al. [18] 2006 Operated 1 187/182 NS (p = 0.19) NR
Taniai et al. [19] 2006 Operated 4 67/41 NS (p = 0.354) NR
Shimizu et al. [20] 2007 Operated 3 70/94 NS (p = 0.738) NR
Tsai et al. [21] 2007 Operated 1 97/58 NS (p = 0.150) S (p = 0.004)
Wang et al. [22] 2007 Operated 3 514/409 NS (p = 0.312) NR
Bockhorn et al. [23] 2008 Operated 4 101/101 NS (p = 0.78) NS (p = 0.28)
Hamady et al. [24] 2008 Operated 4 138/46 NS (p = 0.6) NR
Vigano et al. [25] 2008 Operated 1 55/66 S (p = 0.011) NR
Konopke et al. [26] 2009 Operated 1 70/131 S (p = 0.030) NR
Ng et al. [27] 2009 Operated 2 35/20 NS (p = 0.075) NS (p = 0.43)
Xu et al. [28] 2009 Operated 3 379/290 NS (p > 0.05) NR
Tonelli et al. [29] 2010 Operated 1 70/37 S (p = 0.018) NR
Van der Pool et al. [30] 2010 Operated 1 105/167 NS (p = 0.6) NS (p = 0.3)
Brouquet et al. [31] 2011 Operated 1 47/13 S (p = 0.003) NR
Settmacher et al. [7] 2011 Operated 1 158/224 S (p = 0.033) S (p = 0.003)
Swan et al. [32] 2011 Operated 4 577/625 NS (p = 0.530) NR
Furukawa et al. [33] 2012 Unresectable 1 26/14 NS (p = 0.085) NA
Vigano et al. [34] 2012 Operated 1 182/194 NS NR
Dexiang et al. [35] 2012 All 3 1061/552 S (p < 0.001) NR
Gur et al. [36] 2013 Operated 1 79/79 NS (p = 0.14) S (p = 0.04)
Nanji et al. [37] 2013 Operated 1 125/195 S (p = 0.003) NS (p = 0.092)
Ribeiro et al. [38] 2012 Operated 3 89/81 NS (p = 0.162) NS (p = 0.214)
John et al. [39] 2013 Operated 4 257/174 NS (p = 0.253) NR
Hackl et al. [3] 2014 All 2 1019/407 NS (p = 0.799) NR
Kumar et al. [40] 2014 All 1 1054/542 S (p = 0.003) NR
Kuo et al. [41] 2015 Operated 2 104/55 S (p = 0.001) NR
Ali et al. [42] 2015 Operated 3 66/50 NS (p = 0.997) NR
Kawamura et al. [43] 2016 Operated 1 34/38 S (p = 0.010 NS
Lemke et al. [44] 2016 Operated 3 68/84 S (p = NR) NR
Miller et al. [45] 2017 Operated 3 181/46 NS (p = 0.58) NS (p = 0.87)
Angelsen et al. [46] 2017 Operated 4 39/488 NS (p = 0.068) NR
Bartolini et al. [47] 2018 Operated 1 39/31 NS (p = 0.085) S (p = 0.0001)
Margonis et al. [48] 2018 Operated 3 266/583 S (p = 0.02) NS (p = 0.58)
Marques et al. [49] 2018 Operated 3 95/55 NS (p = 0.505) NS (p = 0.07)
Memeo et al. [50] 2018 Operated 4 753/1031 NS (p = NR) NR
Quireze et al. [51] 2018 All 3 38/16 S (0.036) metachronous worse NS (p = 0.629)
Suthananthan et al. [52] 2018 All 1 276/98 NS (p = 0.172) NR
Strandberg et al. [53] 2018 Operated 1 146/138 S (p = 0.031) NR
Zhao et al. [54] 2018 Operated 1 172/71 NS (p = 0.110) NS (p = 0.088)
  1. *Definition: 1, Time of primary tumour diagnosis/operation; 2, 3 months after primary tumour diagnosis/operation; 3, 6 months after primary tumour diagnosis/operation; 4, 12 months after primary tumour diagnosis/operation. NA not applicable, NR not reported, S significant, NS non-significant, OS overall survival, DFS disease-free survival